Cervical Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 12 – Oct 19, 2026
Emerging Therapeutic targets and Early-phase drug Development in Gynecological Malignancies.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This review examines emerging molecular targets and early-phase drug development strategies for gynecological malignancies, focusing on overcoming treatment resistance through biomarker-driven therapies. The authors highlight novel agents targeting DNA damage response pathways, such as WEE1 and PKMYT1, alongside specific alterations like TP53 Y220C and the rapid expansion of antibody-drug conjugates. For clinicians, these developments represent a significant shift toward precision oncology, offering potential alternatives to conventional chemotherapy for recurrent or treatment-resistant cancers. While tumor heterogeneity and resistance persist, the integration of these targeted therapies into clinical sequencing protocols is essential for improving patient outcomes in oncology practice.
10.1016/j.annonc.2026.10.101
Sep 07 – Sep 14, 2026
Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This exploratory analysis of the phase 3 KEYNOTE-826 trial evaluated 5-year efficacy and safety of pembrolizumab plus platinum-based chemotherapy (with or without bevacizumab) in 617 patients with previously untreated persistent, recurrent, or metastatic cervical cancer. At median follow-up of 59.1 months, overall survival remained significantly improved with pembrolizumab in PD-L1 CPS ≥1 (median 28.6 vs 16.5 months; HR 0.62) and intention-to-treat (26.4 vs 16.8 months; HR 0.64) populations, with sustained progression-free survival benefit (median 10.5 vs 8.2 months; HR 0.58). No new safety signals emerged. These long-term data confirm pembrolizumab plus chemotherapy as a first-line standard-of-care option for recurrent/metastatic cervical cancer.
10.1001/jamaoncol.2026.3547
Jul 27 – Aug 03, 2026
Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This consensus conference convened 33 Gynecologic Cancer InterGroup member groups and diverse stakeholders to standardize clinical trial design and identify unmet needs in cervical cancer research. The group successfully adopted 16 consensus statements covering diagnosis, staging, early-stage disease, locally advanced disease, and persistent or recurrent disease. These statements provide a harmonized framework for academic clinical trials, ensuring that future research addresses critical gaps in gynecologic oncology care. By establishing global standards for trial methodology, this initiative facilitates more rigorous evidence generation to improve survival and quality of life for patients with cervical cancer.
10.1016/S1470-2045(26)00215-9